Back to Bio

InterHealth Has Been Acquired by Lonza

Thursday, October 20, 2016


William Blair acted as financial advisor to InterHealth Nutraceuticals, a portfolio company of Kainos Capital, in connection with its sale to Lonza AG. The sale of InterHealth builds on William Blair’s expertise in advising value-added specialty ingredient businesses.

Transaction Highlights

  • Cross-functional industry expertise: Kainos Capital and InterHealth were attracted to William Blair’s extensive knowledge and experience in the consumer and healthcare verticals, including recent transaction experience and strong relationships with likely strategic and financial acquirers worldwide. The collaboration between William Blair’s consumer and healthcare teams ensured InterHealth’s investment thesis conveyed the compelling attributes of branded nutraceutical ingredients while highlighting the macro drivers of health and wellness trends.
  • Execution excellence leads to premium valuation: William Blair’s team managed a highly competitive strategic and sponsor focused process, driving an exceptional outcome for both InterHealth and Kainos Capital.
  • Highly strategic transaction: The acquisition of InterHealth and its condition-specific, patent-protected ingredients provides an immediate, highly complementary expansion of Lonza’s nutrition business. The U.S. nutrition industry represents a $164 billion market supported by increased usage of condition-specific ingredients as well as an aging baby-boomer population.

About the Companies

Founded in 1987, InterHealth Nutraceuticals is a one-of-a-kind manufacturer and marketer of branded, IP-protected ingredients for the condition-specific nutrition industry. InterHealth pioneered the development of innovative ingredient products such as UC-II and ZMA, and manages an extensive portfolio of science-backed ingredients, which are validated by extensive third-party research and testing.

Kainos Capital is a leading middle-market private investment firm focused on the food and consumer sector. The principals of Kainos have crafted a strong track record of helping companies improve performance over the long term, and as a result of their sector focus and experience, enjoy a reputation as an “investor of choice” in the food and consumer industry.

Lonza AG, based in Basel, Switzerland, is a worldwide leader supplying the pharmaceutical, biopharmaceutical, and specialty ingredients industries with state-of-the-art products, services, and research. Lonza harnesses science and technology to create products that make people’s and animals’ lives healthier and that enhance the overall quality of life and well-being.

More about our consumer and retail investment banking practice

More about our healthcare investment banking expertise